Liquid Chromatographic Determination of 4-Amino-N-(2,6-dimethylphenyl)-benzamide in Rat Serum and Urine

Abstract

The compound 4-amino-N-(2,6-dimethylphenyl)-benzamide has shown potential as a new anticonvulsant. A method for the liquid chromatographic determination of serum and urine concentrations of the compound and its N-acetylated metabolite was developed for pharmacokinetic studies. Quantitation was achieved via UV detection at 275 nm following isocratic reversed phase (C₁₈) separation using a ternary solvent system of water:acetonitrile:acetic acid (60:39:1) at a flow rate of 1.5 mL/min. The compounds were isolated from a 50 μL sample of serum using solid phase extraction with prior protein precipitation. The compounds and internal standard were eluted from the extraction column with acetonitrile. Isolation from urine was achieved similarly with the exclusion of protein precipitation. The assay procedure is useful for the determination of concentrations of parent compound from 0.68 to 204.6 μg/mL.     

Extraction of nitrofurantoin and its toxic metabolite from urine by supercritical fluids. Quantitation by high performance liquid chromatography with UV detection

A procedure is described for the determination of nitrofurantoin and its toxic metabolite in urine from patients with urinary infection using supercritical fluid extraction (SFE) and liquid chromatography. The standard solution of toxic metabolite (radical anion) was obtained by electrochemical reduction of nitrofurantoin in an aprotic medium and chemical reoxidation with oxygen. In our initial SFE studies to find the adequate extraction parameters, drug solutions were impregnated onto filter paper. Quantitative extractions were achieved when the experiments were carried out under 2500 psi of pressure at a temperature of 80 °C (oven and restrictor) after 20 min of static extraction and 5 min of dynamic extraction. The modifier used was acetonitrile (2.0 ml in a 10 ml extraction column). Nitrofurantoin and its toxic metabolite were detected in urine samples. Both compounds were quantified in the extracts by high performance liquid chromatography (HPLC) with detection at 310 nm. The calibration graph of these compounds in acetonitrile was linear between 10.9 and 378.0 μM (R=0.9995) for nitrofurantoin and between 3.0×10⁻³ and 21.0 μM (R=0.9992) for the metabolite. The detection limits (LOD) were 12.1 and 0.9 μM, respectively. The drug was administered to two patients during 7 days, and all the urine eliminated between 1 day before and 2 days after administration was analyzed. One patient consumed the drug in the form of microcrystals and the other as macrocrystals.     

Detection of catecholamine metabolites in urine based on ultra-high-performance liquid chromatography–tandem mass spectrometry

The excretion of neurotransmitter metabolites in normal individuals is of great significance for health monitoring. A rapid quantitative method was developed with ultra-performance liquid chromatography–tandem mass spectrometry. The method was further applied to determine catecholamine metabolites vanilymandelic acid (VMA), methoxy hydroxyphenyl glycol (MHPG), dihydroxy-phenyl acetic acid (DOPAC), and homovanillic acid (HVA) in the urine. The urine was collected from six healthy volunteers (20–22 years old) for 10 consecutive days. It was precolumn derivatized with dansyl chloride. Subsequently, the sample was analyzed using triple quadrupole mass spectrometry with an electrospray ion in positive and multireaction monitoring modes. The method was sensitive and repeatable with the recoveries 92.7–104.30%, limits of detection (LODs) 0.01–0.05 μg/mL, and coefficients no less than 0.9938. The excretion content of four target compounds in random urine samples was 0.20 ± 0.086 μg/mL (MHPG), 1.27 ± 1.24 μg/mL (VMA), 3.29 ± 1.36 μg/mL (HVA), and 1.13 ± 1.07 μg/mL (DOPAC). In the urine, the content of VMA, the metabolite of norepinephrine and adrenaline, was more than MHPG, and the content of HVA, the metabolite of dopamine, was more than DOPAC. This paper detected the levels of catecholamine metabolites and summarized the characteristics of excretion using random urine samples, which could provide valuable information for clinical practice.     

Studies on the distribution and concentration of thiamine in blood and urine

Studies are reported resulting in a reliable procedure for estimating the thiamine content in human blood and urine. For the determination in blood, heparinized blood is hemolyzed with 0.3 N hydrochloric acid at 100 °C. Cocarboxylase is then converted to free thiamine by means of wheat germ acid phosphatase at pH 5.0 in an acetate buffer. The liberated thiamine is adsorbed to a CG-50 (Rohm & Haas) carboxylic acid ion exchange acrylic resin column and then eluted with 1 N H₂SO₄. The thiamine is then oxidized to thiochrome and extracted with n-butyl alcohol, at pH 9.8–10.0, in the presence of disodium phosphate. Readout is by fluorometry at an excitation wavelength of 371 nm and an emission wavelength of 425 nm. The range found for thiamine in whole blood by this procedure on 18 normal adults was 1.9–3.9 μg/100 ml, with a mean value of 2.77 μg/100 ml of whole blood. The mean recovery of 12 recovery experiments was 94.1%. The same procedure is applicable to the determination of thiamine in urine. Conversion of cocarboxylase to free thiamine is not necessary since it was determined that practically all of the thiamine found in urine is not phosphorylated. Urine values were variable, the range for 11 healthy adults being 5.6–77.9 μg/100 ml with a mean value of 19.2 μg/100 ml. This corresponds to a value of 346 μg of thiamine/24 hours.     

Pharmacokinetics and excretion study of bergenin and its phase II metabolite in rats by liquid chromatography tandem mass spectrometry

A sensitive and selective liquid chromatographic–tandem mass spectrometric (LC–MS/MS) method for the determination of bergenin and its phase II metabolite in rat plasma, bile and urine has been developed. Biological samples were pretreated with protein precipitation extraction procedure and enzymatic hydrolysis method was used for converting glucuronide metabolite to its free form bergenin. Detection and quantitation were performed by MS/MS using electrospray ionization and multiple reaction monitoring. Negative electrospray ionization was employed as the ionization source. Sulfamethoxazole was used as the internal standard. The separation was performed on a reverse‐phase C₁₈ (250 × 4.6 mm, 5 μm) column with gradient elution consisting of methanol and 0.5% aqueous formic acid. The concentrations of bergenin in all biological samples were in accordance with the requirements of validation of the method. After oral administration of 12 mg/kg of the prototype drug, bergenin and its glucuronide metabolite were determined in plasma, bile and urine. Bergenin in bile was completely excreted in 24 h, and the main excreted amount of bergenin was 97.67% in the first 12 h. The drug recovery in bile within 24 h was 8.97%. In urine, the main excreted amount of bergenin was 95.69% in the first 24 h, and the drug recovery within 24 h was <22.34%. Total recovery of bergenin and its glucuronide metabolite was about 52.51% (20.31% in bile within 24 h, 32.20% in urine within 48 h). The validated method was successfully applied to pharmacokinetic and excretion studies of bergenin.     

Can Humans Metabolize Arsenic Compounds to Arsenobetaine?

Arsenic compounds were determined in 21 urine samples collected from a male volunteer. The volunteer was exposed to arsenic through either consumption of codfish or inhalation of small amounts of (CH₃)₃As present in the laboratory air. The arsenic compounds in the urine were separated and quantified with an HPLC–ICP–MS system equipped with a hydraulic high-pressure nebulizer. This method has a determination limit of 0.5 μg As dm⁻³ urine. To eliminate the influence of the density of the urine, creatinine was determined and all concentrations of arsenic compounds were expressed in μg As g⁻¹ creatinine. The concentrations of arsenite, arsenate and methylarsonic acid in the urine were not influenced by the consumption of seafood. Exposure to trimethylarsine doubled the concentration of arsenate and increased the concentration of methylarsonic acid drastically (0.5 to 5 μg As g⁻¹ creatinine). The concentration of dimethylarsinic acid was elevated after the first consumption of fish (2.8 to 4.3 μg As g⁻¹ creatinine), after the second consumption of fish (4.9 to 26.5 μg As g⁻¹ creatinine) and after exposure to trimethyl- arsine (2.9 to 9.6 μg As g⁻¹ creatinine). As expected, the concentration of arsenobetaine in the urine increased 30- to 50-fold after the first consumption of codfish. Surprisingly, the concentration of arsenobetaine also increased after exposure to trimethylarsine, from a background of approximately 1 μg As g⁻¹ creatinine up to 33.1 μg As g⁻¹ creatinine. Arsenobetaine was detected in all the urine samples investigated. The arsenobetaine in the urine not ascribable to consumed seafood could come from food items of terrestrial origin that—unknown to us—contain arsenobetaine. The possibility that the human body is capable of metabolizing trimethyl- arsine to arsenobetaine must be considered. © 1997 by John Wiley & Sons, Ltd.     

High Pressure Liquid Chromatographic Assay for Salicylic Acid and its Metabolites in Rat Urine

Abstract

An HPLC method for the determination of salicylic acid (SA), gentisic acid (GA), salicyluric acid (SU), and salicyl acyl glucuronide (SAG) in rat urine was developed. The method consisted of extracting SA, GA, and SU from acidified urine into 50:50 mixture of ethyl acetate and butyl chloride. Salicyl acyl glucuronide was extracted from neutral urine after conversion to salicyl hydroxamic acid with hydroxylamine. Salicyl phenolic glucuronide was estimated indirectly as the difference between total salicylate and sum of the four constituents mentioned above. Chromatographic separation was done on a C₁₈ column with U.V. detection at 310 nm using a mobile phase consisting of 5–10% acetonitrile in 3% glacial acetic acid. The extraction recovery of these compounds from spiked urine ranged from 90–108%. The detection limits were 10 μg/ml for GA, SU and SA, and 2.5 μg/ml for SHA. The method was applied to the study of salicylic acid metabolism in the rat.     

The determination of phenobarbital and diphenylhydantoin in blood by differential pulse polarography

A sensitive differential pulse polarographic assay was developed for the determination of phenobarbital or diphenylhydantoin in blood. The assay involves the selective extraction of the compound into chloroform from whole blood buffered to pH 7.0. After suitable “clean-up” of the sample, each compound is nitrated in 10% potassium nitrate in sulfuric acid at 25° for 1 h. The nitro-derivatives are extracted into ethyl acetate, and the residues are dissolved in 1 M phosphate buffer (pH 7.0) or 0.1 M sodium hydroxide for phenobarbital and diphenylhydantoin, respectively; the solutions are deoxygenated, and analyzed by differential pulse polarography. The overall recovery of phenobarbital and diphenylhydantoin from blood was 72.3% ±6.5 (s_r) and 76.7 ±2.3 (s_r) respectively. The sensitivity limit is 1–2 μg ml^-1 of blood for both compounds. A modified assay for the determination of both compounds in blood with t.l.c. separation was also developed.     

Evaluation of pharmacokinetics,bioavailability and urinary excretion of scopolin and its metabolite scopoletin in Sprague Dawley rats by liquid chromatography–tandem mass spectrometry

We aimed to investigate the pharmacokinetics, bioavailability and urinary excretion of scopolin and its metabolite scopoletin in rats. An LC–tandem mass spectrometry (MS/MS) method for simultaneous determination of scopolin and scopoletin in rat biomatrices was developed and validated over a plasma and urine concentration range of 5.0–2000 ng/mL. Chromatographic separation was performed on a Hypersil GOLD C₁₈ column with acetonitrile and 0.1% formic acid in water as mobile phase with gradient elution. Detection was performed in the positive ionization and selected reaction monitoring mode. The intra‐ and inter‐batch precision and accuracy, extraction recovery and matrix effect and stability of scopolin and scopoletin were well within the acceptable limits of variation. There was no gender‐related difference in the pharmacokinetic profiles of scopolin. There were significant differences in total area under the concentration–time curve (AUC), time required to achieve a maximal concentration (T_max) and apparent clearance from plasma (Cl/F) of scopoletin between the male and female rats (p < .05). The bioavailability (F) of scopolin was exceptionally low. The maximal excretion rates were 7.61 μg/h and 7.15 μg/h for scopolin and 31.68 μg/h and 25.58 μg/h for scopoletin in male and female rats, respectively. The LC–MS/MS method was successfully applied to the pharmacokinetic, bioavailability and urinary excretion studies of scopolin and its metabolite scopoletin following a single administration of scopolin to rats.     

Headspace single-drop microextraction coupled with gas chromatography electron capture detection of butanone derivative for determination of iodine in milk powder and urine

A new detection method using headspace single-drop microextraction (HS-SDME) coupled to gas chromatography (GC) was established to determine the iodine in milk powder and urine. The derivative from the reaction between iodine and butanone in the acidic media was extracted into a micro-drop then determined by GC-ECD. With the optimisation of HS-SDME and derivatisation, the calibration curve showed good linearity within the range of 0.004–0.1 μg mL^?1 (0.004–0.1 μg g^?1) (R ² = 0.9991), and the limits of detection for milk powder and urine were 0.0018 μg g^?1 and 0.36 μg L^?1, respectively. The mean recoveries of milk powder and urine were 90.0–107 % and 89.4–101 % with mean RSD of 1.7–3.4 % and 2.7–3.3 %, respectively. This detection method affords a number of advantages, such as being simple, rapid, and inexpensive, with low organic solvent consumption, and is remarkably free from interference effects, rendering it an efficient method for the determination of iodine in milk powder and urine samples.     

Simple High-Performance Liquid Chromatographic Assay, with Post-Column Derivatization, for Simultaneous Determination of Mycophenolic Acid and its Glucuronide Metabolite in Human Plasma and Urine

Two simple high-performance liquid chromatographic (HPLC) methods have been established for simultaneous determination of mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) in human urine, and of their total and unbound forms in human plasma. For total MPA and MPAG analysis sample preparation entailed precipitation of protein with acetonitrile and isolation of the free analytes from the plasma by ultrafiltration. For urine samples, fivefold dilution with water was used. MPAG was determined by UV detection whereas MPA was quantified by fluorescence detection after post-column derivatization with 0.2 M sodium hydroxide solution. For plasma, response was found to be linearly dependent on concentration over the ranges 0.1–40 μg mL^-1 and 0.01–1 μg mL^-1 for total and free MPA, respectively, and 10–200 μg mL^-1 and 2.5–100 μg mL^-1 for total and free MPAG, respectively. For urine, linearity was observed from 0.1 to 50 μg mL^-1 for MPA and 10 to 500 μg mL^-1 MPAG in the urine before dilution. The methods reported were found to be accurate and reproducible for quantifying the level of MPA and MPAG and can thus be used for clinical pharmacokinetic studies and for therapeutic drug monitoring. Contributed equally to this work An erratum to this article is available at .     

A rapid MCM‐41 dispersive micro‐solid phase extraction coupled with LC/MS/MS for quantification of ketoconazole and voriconazole in biological fluids

A rapid dispersive micro‐solid phase extraction (D‐μ‐SPE) combined with LC/MS/MS method was developed and validated for the determination of ketoconazole and voriconazole in human urine and plasma samples. Synthesized mesoporous silica MCM‐41 was used as sorbent in d ‐μ‐SPE of the azole compounds from biological fluids. Important D‐μ‐SPE parameters, namely type desorption solvent, extraction time, sample pH, salt addition, desorption time, amount of sorbent and sample volume were optimized. Liquid chromatographic separations were carried out on a Zorbax SB‐C₁₈ column (2.1 × 100 mm, 3.5 μm), using a mobile phase of acetonitrile–0.05% formic acid in 5 mm ammonium acetate buffer (70:30, v /v). A triple quadrupole mass spectrometer with positive ionization mode was used for the determination of target analytes. Under the optimized conditions, the calibration curves showed good linearity in the range of 0.1–10,000 μg/L with satisfactory limit of detection (≤0.06 μg/L) and limit of quantitation (≤0.3 μg/L). The proposed method also showed acceptable intra‐ and inter‐day precisions for ketoconazole and voriconazole from urine and human plasma with RSD ≤16.5% and good relative recoveries in the range 84.3–114.8%. The MCM‐41‐D‐μ‐SPE method proved to be rapid and simple and requires a small volume of organic solvent (200 μL); thus it is advantageous for routine drug analysis.     

Speciation of Arsenic Compounds in the Urine of Rats Orally Exposed to Dimethylarsinic Acid Ion Chromatography with ICP–MS as an Element-Selective Detector

A combined ion chromatography (IC) with inductively coupled plasma mass spectrometry (ICP—MS) system as an element-selective detector has been used for the determination of arsenic compounds. Seven arsenic compounds were separated by cation-exchange chromatography. Subsequently, the separated arsenic compounds were directly introduced into the ICP—MS and were detected at m/z =75. Detection limits for the seven arsenic compounds ranged from 0.8 to 3.8 μg As/l. The IC–ICP–MS system was applied to the determination of arsenic compounds in the urine of dimethylarsinic acid (DMAA)-exposed rats. DMAA was the most abundant arsenic compound detected. Arsenous acid, monomethylarsonic acid and trimethylarsine oxide were also detected.     

Determination of antifouling pesticides and their degradation products in marine sediments by means of ultrasonic extraction and HPLC–APCI–MS

A method has been developed for the simultaneous determination of antifouling pesticides and some of their degradation products, e.g. dichlofluanid, diuron, demethyldiuron, 1-(3,4-dichlorophenyl)urea, sea-nine, Irgarol 1051 and one of its metabolites (2-methylthio-4-tert-butylamino-s-triazine) in marine sediments. The determination of these compounds in sediment samples was performed by means of methanolic ultrasonic extraction then clean-up on an Isolute ENV+ solid phase extraction (SPE) cartridge. The resulting extract was then analyzed by reversed-phase high-performance liquid chromatography coupled with atmospheric-pressure chemical-ionization mass spectrometry in negative and positive ion modes (HPLC–APCI–MS). Recovery ranged from 54–109% for the antifouling agents and their degradation products. The determination limits for the different compounds varied between 0.2 and 1.6 μg kg^–1 dry sediment. The analytical procedure was successfully applied to the determination of these pesticides and their degradation products in marine sediment samples from different marinas of the Catalan coast. The compounds detected were: diuron, dichlofluanid, demethyldiuron, sea-nine, and Irgarol 1051. The highest concentrations were those of diuron and Irgarol 1051 – 136 and 88 μg kg^–1, respectively.     

Simultaneous determination of trifloxystrobin and trifloxystrobin acid residue in rice and soil by a modified quick,easy, cheap,effective, rugged,and safe method using ultra high performance liquid chromatography with tandem mass spectrometry

A sensitive analytical method for the simultaneous determination of trifloxystrobin and its metabolite trifloxystrobin acid in rice including straw, bran, brown rice and soil was developed by using ultra high performance liquid chromatography coupled with tandem mass spectrometry. The fungicide trifloxystrobin and its metabolite trifloxystrobin acid were extracted using acetonitrile with 1% formic acid v/v and subsequently cleaned up by primary secondary amine, octadecylsilane or graphitized carbon black prior to ultra high performance liquid chromatography coupled with tandem mass spectrometry. The determination of two target compounds was achieved in less than 3 min using an electrospray ionization source in positive mode. The limits of detection were below 0.22 μg/kg and the limits of quantification did not exceed 0.74 μg/kg in all matrices, which were much lower than the maximum residue levels established by the Codex Alimentarius Commission. The overall average recoveries in four matrix at three levels (0.1, 1.0 and 5.0 mg/kg) ranged from 74.2 to 107.4% with a relative standard deviations of less than 7.8% (n = 5) for both analytes. The method was demonstrated to be convenient and reliable for the routine monitoring of trifloxystrobin and its metabolite. The developed method was validated and applied for the analysis of degradation study samples.     

Solid phase extraction for GC-FID determination of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and methamphetamine (MA) in human urine

A simple solid phase extraction method was developed for estimating the amounts of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and methamphetamine (MA) in urine by using the GC-FID technique. The urine sample was alkalinized prior to undergoing solid phase extraction using Oasis HLB®. A 5% methanol-water mixture containing 2% ammonium hydroxide was used for washing, whereas a 70% methanol-water mixture containing 2% acetic acid was used for elution. The compounds were analyzed using the standard GC-FID conditions previously established for ecstasy samples, i.e., column: CP-SIL 24 CB WCOT (30 m × 0.32 mm i.d., 0.25 μm film thickness); carrier gas: N₂ (2.6 mL/min); injector temperature: 290°C; detector temperature: 300°C; oven temperature: initial 80°C, final 270°C (1 min), ramp rate 20°C/min. Validation demonstrated the linearity of the calibration curves between 1 and 20 μg/mL (r > 0.99) for all analytes. The precisions (% RSD) were approximately 3–17%, 6–16% and 7–17% for MDMA, MDA and MA, respectively. The accuracies (% DEV) were (?)17-(+)5%, (?)18-(+)15% and (?)18-(+)0.6% for MDMA, MDA and MA, respectively. The recovery ranged from 80 to 107% and the lower limit of quantification (LLOQ) was 1 μg/mL. The method was successfully applied to determine the levels of these compounds in the urine of drug abuse suspects.     

Determination of Carbamazepine and its Main Metabolite Carbamazepine-10,11-Epoxide in Rat Brain Microdialysate and Blood Using ESI–LC–MS (Ion Trap)

A new analytical method has been developed and validated for determination of the anti-epileptic drug carbamazepine (CBZ) and its main metabolite carbamazepine-10,11-epoxide (CBZ-E) using ESI–LC–MS (ion trap). The compounds were separated on a C18 (150 × 2.1 mm I.D., 3 μm particles) column and were isocratically eluted in the mobile phase consisting of water–acetonitrile–acetic acid (74.5:25:0.5, v/v) using the flow rate of 0.4 mL min⁻¹. The other anti-epileptic drug oxcarbamazepine (OXC) was used as an internal standard. The retention times for CBZ-E, OXC and CBZ were 5.6, 6.8, 12.8 min. Signals of the compounds were monitored under multi-reaction monitoring mode (MRM) of ESI–LC–MS (ion trap) for the quantification. Selected ions of CBZ-E, OXC and CBZ in MRM were m/z 253→210, m/z 253→180 and m/z 237→194. The method was validated over the concentration range of 5.0–500.0 ng mL⁻¹ and was applied to rat brain microdialysate and blood samples for the determination of CBZ and main metabolite. The brain microdialysate and the blood sample were collected simultaneously after intra-peritoneal injection of CBZ (12 mg kg⁻¹) during a period of 10 h. No interference from endogenous substances and matrix effect were found on the separation of microdialysates and blood samples. The consequent signals of the compounds were resolved and integrated clearly. The LC–MS method was presented as an alternative to investigate pharmacokinetic parameters of CBZ and CBZ-E in blood and brain studies.

     

Capillary zone electrophoresis applied to the determination of the angiotensin-converting enzyme inhibitor cilazapril and its active metabolite in pharmaceuticals and urine

A capillary zone electrophoresis method has been developed for the quantitation of antihypertensive drug cilazapril and its active metabolite cilazaprilat in pharmaceuticals and urine. The separation of the compounds was performed in a fused-silica capillary filled with the running electrolyte, which consisted of a 60 mM borate buffer solution at pH 9.5. Under the optimized experimental conditions, the separation took less than 5 min. The analysis of urine samples required a previous solid-phase extraction step using C8 cartridges. The method was successfully applied to the determination of the drug and its metabolite in urine samples obtained from three hypertensive patients (detection limits of 115 ng ml(-1) for cilazaprilat and 125 ng ml(-1) for cilazapril) and to pharmaceutical dosage forms. The method was validated in terms of reproducibility, linearity and accuracy.     

A Validated Ion-Pairing High Performance Liquid Chromatographic Method for the Determination of Enoxacin and its Metabolite Oxo-Enoxacin in Plasma and Urine

Abstract

A rapid, sensitive, and specific determination of enoxacin and its principal metabolite, oxo-enoxacin, in plasma and urine is described. the method, which employs the structurally related compound ciprof loxac in as internal standard, involves a protein precipitation step for plasma and solid-phase extraction for urine. Liquid chromatographic analysis is carried out on a C-18 bonded silica column; the mobile phase consists of 0.1 M citric-acid/acetonitrile employing ammonium perchlorate and tetrabutyl-ammonium hydroxide as ion-pairing agents. Quantitation is performed by UV-detection at 340 nm.

The analytical method was validated by examining the performance characteristics specificity, linearity, precision, accuracy, sensitivity, and recovery. Enoxacin calibration curves were linear between 0.02 and 3.2 μg/ml of plasma and from 0.5 to 125 μg/ml of urine. Limits of quantitation in plasma and urine were 0.01 and 0.5 μg/ml, respectively. For oxo-enoxacin, linear of calibration curves were obtained i n the range 0.05 to 1.6 μg/ml (plasma) and 1 to 50 μg/ml (urine); the respective quantitation limits were approximately 0.02 and 1 μg/ml.

The present assay procedure has been applied to monitoring plasma and urine concentrations in several pharmacokinetic studies in humans and different animal species.     

Enzyme co-immobilization for the sequential determination of lactic acid and glucose in serum

An enzymatic method for the sequential determination of lactic acid and glucose is proposed. Sample matrix effects are overcome by using an internally coupled valve system. The problem arising from the dissimilar concentrations of the two analytes commonly occurring in serum is solved by applying the scale-expansion technique with a diode-array spectrophotometer. The determination ranges are 10–400 and 2–100 μg ml^?1 for lactic acid and glucose, respectively (r.s.d. 1.63 and 2.30%; n=11). Mixtures of these compounds in ratios up to 1:10 can be readily resolved, which allows their determination in serum with good results.